ACADIA PHARMACEUTICALS INC. Gain (Loss) on Investments
ACADIA PHARMACEUTICALS INC. (ACAD) reported Gain (Loss) on Investments of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnInvestments · last filed 2026-02-26
- ACADIA PHARMACEUTICALS INC. gain (loss) on investments for the quarter ending 2024-12-31 was $0.00.
- ACADIA PHARMACEUTICALS INC. gain (loss) on investments for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. gain (loss) on investments for the quarter ending 2024-06-30 was $0.00.
- ACADIA PHARMACEUTICALS INC. gain (loss) on investments for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. gain (loss) on investments for fiscal 2025 was $0.00.
- ACADIA PHARMACEUTICALS INC. gain (loss) on investments for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. gain (loss) on investments for fiscal 2023 was $5.11M, a 44.24% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. gain (loss) on investments for fiscal 2022 was $3.54M, a 52.08% increase from fiscal 2021.
| Period end | Gain (Loss) on Investments 3 month | Gain (Loss) on Investments 6 month | Gain (Loss) on Investments 9 month | Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $1.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $1.51M derived: sum of 3 quarters · filed 2026-02-26 | $264.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.51M derived: sum of 2 quarters · filed 2026-02-26 | $264.00K derived: sum of 3 quarters · filed 2026-02-26 | $5.11M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $264.00K derived: sum of 2 quarters · filed 2024-11-07 | $5.11M 10-Q · filed 2024-11-07 | $6.65M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $3.60M 10-Q · filed 2024-08-07 | $5.14M derived: sum of 3 quarters · filed 2025-02-27 | $7.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $4.84M 10-Q · filed 2024-05-09 | $6.39M derived: sum of 2 quarters · filed 2025-02-27 | $8.54M derived: sum of 3 quarters · filed 2025-02-27 | $8.05M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.70M derived: sum of 2 quarters · filed 2025-02-27 | $3.20M derived: sum of 3 quarters · filed 2025-02-27 | $3.54M 10-K · filed 2025-02-27 |
| 2022-09-30 | $2.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $1.66M derived: sum of 2 quarters · filed 2023-11-03 | $2.00M 10-Q · filed 2023-11-03 | $3.62M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$497.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$158.00K 10-Q · filed 2023-08-03 | $1.47M derived: sum of 3 quarters · filed 2024-02-28 | $1.85M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $339.00K 10-Q · filed 2023-05-08 | $1.96M derived: sum of 2 quarters · filed 2024-02-28 | $2.35M derived: sum of 3 quarters · filed 2024-02-28 | $2.52M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.01M derived: sum of 2 quarters · filed 2024-02-28 | $2.18M derived: sum of 3 quarters · filed 2024-02-28 | $2.33M 10-K · filed 2024-02-28 |
| 2021-09-30 | $383.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $561.00K derived: sum of 2 quarters · filed 2022-11-03 | $706.00K 10-Q · filed 2022-11-03 | $971.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $178.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $323.00K 10-Q · filed 2022-08-09 | $588.00K derived: sum of 3 quarters · filed 2023-02-28 | $386.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $145.00K 10-Q · filed 2022-05-05 | $410.00K derived: sum of 2 quarters · filed 2023-02-28 | $208.00K derived: sum of 3 quarters · filed 2023-02-28 | $645.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $265.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $63.00K derived: sum of 2 quarters · filed 2023-02-28 | $500.00K derived: sum of 3 quarters · filed 2023-02-28 | -$997.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | -$202.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $235.00K derived: sum of 2 quarters · filed 2021-11-09 | -$1.26M 10-Q · filed 2021-11-09 | -$771.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $437.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$1.06M 10-Q · filed 2021-08-05 | -$569.00K derived: sum of 3 quarters · filed 2022-03-01 | $178.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$1.50M 10-Q · filed 2021-05-06 | -$1.01M derived: sum of 2 quarters · filed 2022-03-01 | -$259.00K derived: sum of 3 quarters · filed 2022-03-01 | -$271.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $491.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.24M derived: sum of 2 quarters · filed 2022-03-01 | $1.23M derived: sum of 3 quarters · filed 2022-03-01 | $997.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | $747.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $735.00K derived: sum of 2 quarters · filed 2020-11-04 | $506.00K 10-Q · filed 2020-11-04 | $633.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$241.00K 10-Q · filed 2020-08-06 | -$114.00K derived: sum of 3 quarters · filed 2021-02-25 | -$1.83M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$229.00K 10-Q · filed 2020-05-08 | -$102.00K derived: sum of 2 quarters · filed 2021-02-25 | -$1.82M derived: sum of 3 quarters · filed 2021-02-25 | -$2.02M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$1.59M derived: sum of 2 quarters · filed 2021-02-25 | -$1.79M derived: sum of 3 quarters · filed 2021-02-25 | -$1.84M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$1.92M derived: sum of 2 quarters · filed 2019-10-31 | -$1.97M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | -$200.00K 10-Q · filed 2018-08-08 | -$247.00K 10-Q · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |